Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
07:40pm, Tuesday, 10'th Mar 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
2 Under-the-Radar Stocks to Buy and Hold
01:13pm, Tuesday, 10'th Mar 2026
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision
03:43pm, Monday, 09'th Mar 2026
32,410 shares were exercised and sold for a total transaction value of ~$6.0 million on February 2, 2026. After this transaction, Tabuteau directly held 7,229 shares and indirectly held 7,344,500 shar
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 25'th Feb 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
01:11pm, Tuesday, 24'th Feb 2026
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued
12:25pm, Monday, 23'rd Feb 2026
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade
Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings
12:00pm, Monday, 23'rd Feb 2026
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
11:35am, Monday, 23'rd Feb 2026
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago.
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
11:34am, Monday, 23'rd Feb 2026
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:00am, Monday, 23'rd Feb 2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
GSA Capital Partners LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM
05:52am, Monday, 23'rd Feb 2026
GSA Capital Partners LLP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to the company in its most recent disclosure with the Securities and
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036
01:00am, Sunday, 22'nd Feb 2026
Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either.
AI, Clean Energy & Health Stocks: The Big Winners in a Multipolar 2026
03:01pm, Friday, 20'th Feb 2026
NVIDIA, Albemarle and Axsome Therapeutics emerge as standout plays as AI, clean energy and healthcare draw massive capital in a split 2026 market.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of “Moderate Buy” from Analysts
01:38am, Thursday, 19'th Feb 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen analysts that are currently covering the company, MarketBeat Rati
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
07:00am, Tuesday, 17'th Feb 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,
